Questions and Answers
Yes. TMR® acts on both nociceptive pain and neuropathic pain. Evidence can be found in the literature and in particular in the scientific article by Prof. Piaggesi entitled “Safety and effectiveness of therapeutic magnetic resonance in the management of postsurgical lesion of the diabetic foot” (http://www.ncbi.nlm.nih.gov/pubmed/25724594) where it is shown to be effective in reducing pain during the treatment period with TMR® and for several months following termination of therapy.
The therapy is administered in sessions lasting approximately 30 minutes, 1 to 4 times a day, for a period varying from 4 to 8 weeks, depending on the severity and type of condition. The therapy may be extended for a longer lasting effect, especially when used for pain and for orthopaedic conditions.
DIAPASON® is a medical device designed for home use. The patient can rent it on a monthly basis, or purchase it, by contacting our office, which will provide all the information necessary to complete the process. The product is delivered directly to the patient’s home by one of our trusted couriers and the rental cost includes THERESON Customer Service, which is available for the patient for any needs.
While using DIAPASON® it is possible that local phenomena such as redness or mild tingling will occur. These events are an indication of a proper functioning of the device and are due to the natural process of restorative response of biological tissues.
Two clinical trials were completed, one of them multicentre, with the participation of the Cisanello University Hospital of Pisa, Cà Foncello Hospital of Treviso and the Pederzoli Nursing Home of Peschiera del Garda, and one of them single centre, at the Cisanello University Hospital of Pisa, on two groups of patients with postsurgical diabetic foot lesions.
No, it is different. While both methods are based on electromagnetic fields, TMR® uses a stimulation signal with varying frequencies, in the range 0-250 Hz, optimised to induce cellular responses specific for the healing of ulcers. The signal is formed from triangular-shaped pulse sequences and the amplitudes are not constant, which favour the mechanisms of cell replication and the reduction of oxidative stress (evidence obtained in vitro and published in June 2015 in the specialised and international magazine, “Journal of Tissue Engineering and Regenerative Medicine “).
DIAPASON® is a patented device (patent # 0001406269) with the patent title: “Apparatus for therapeutic treatment with pulsed electromagnetic waves resonating.” Another patent (# TO2014A000505) was also submitted entitled “System for therapeutic treatments with electromagnetic waves” for which we received a favourable research report that permits us to proceed with the extension of the application at European level.
Yes, in some instances a reduction in pain occurs from the second week of treatment forward.
Under the circular of the Italian Ministry of Health dated 28/03/2013, THERESON S.p.A informs the user that site content (text, images, etc.) is exclusively intended for health workers and the content found within is solely informational. The information therein does not, therefore, qualify as advertising.
THERESON S.p.A. accepts no responsibility for any consultation by persons who are not professionals.